Patrys Limited Stock: price and insider trades · Australia
No insider purchase over the last 90 days. The latest, by Unknown, was filed 03 Jul 2026.
Patrys Limited: what insiders have been doing
Every trade that managers of Patrys Limited disclose to ASX is tracked on this page. 2 insiders have disclosed 2 filings since 8 November 2025.
Only purchases show up on the open market, 1 purchase in all worth €18k, filed by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Among those who bought: 1 senior executive. At €18k, the purchase published on 3 July 2026 by Peter Christie is the largest of the period (0.26% of market cap).
For context, the typical company on the same exchange (median of 2,535 companies) published 3 filings over the same period, against 2 filings here. Our records for Patrys Limited go back to 2026, with 1 purchase and no sales on the open market in total.
The last purchase on record was published on 3 July 2026, which is 128 days ago.
This summary is built from ASX disclosures alone and does not predict where the share price will go.
Who traded when
BuySaleSince the insiders bought
- Unknown-30.8%Entry A$0.04 · Close 16 Oct 2026 A$0.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
- ShareASXISIN AU000000PAB9ASX:2924-03108790-6A1332892
- ▲Unknown30,000 AUD27ASX1,250,000 shares@ A$0.0240.26% mcap100.0% of flowShareASXISIN AU000000PAB9ASX:2924-03107817-6A1332480Canonical exit: 1 Oct 2026 (T+90)
2 of 2 declarations
About Patrys Limited
Patrys Limited is a company listed on the Australian Securities Exchange (ASX) that focuses on developing innovative cancer treatments. The company utilizes advanced technologies to create targeted therapies.